UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Arthritis research & therapy, 2024-02, Vol.26 (1), p.49-49, Article 49

2024

Volltextzugriff (PDF)

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Arthritis research & therapy, 2021-01, Vol.23 (1), p.41-41, Article 41

2021

Volltextzugriff (PDF)

P2Y2 receptors regulate osteoblast mechanosensitivity during fluid flow

American Journal of Physiology: Cell Physiology, 2014-06, Vol.306 (11), p.C1058-C1067

2014

Volltextzugriff (PDF)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks

BMC rheumatology, 2021-09, Vol.5 (1), p.50-9, Article 50

2021

Volltextzugriff (PDF)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

Rheumatology (Oxford, England), 2020-12, Vol.59 (12), p.3834-3844

2020

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

Journal of rheumatology, 2023-08, Vol.50 (8), p.1020

2023

Volltextzugriff (PDF)

P187 Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year results from the COAST programme

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

P172 Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment

Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1)

2021

Volltextzugriff (PDF)

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

Journal of rheumatology, 2022-03, Vol.49 (3), p.265

2022

Volltextzugriff (PDF)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Clinical rheumatology, 2022-10, Vol.41 (10), p.3035-3047

2022

Volltextzugriff (PDF)

P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Clinical rheumatology, 2022-10, Vol.41 (10), p.3261-3261

2022

Volltextzugriff (PDF)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

Rheumatology (Oxford, England), 2021-11, Vol.60 (11), p.5485-5485

2021

Volltextzugriff (PDF)

P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF-α inhibitor-experienced) trials at 52 weeks

Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1)

2021

Volltextzugriff (PDF)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial

Rheumatology and therapy., 2021-03, Vol.8 (1), p.135-150

2021

Volltextzugriff (PDF)

P2Y^sub 2^ receptors regulate osteoblast mechanosensitivity during fluid flow

American Journal of Physiology: Cell Physiology, 2014-06, Vol.306 (11), p.C1058

2014

Volltextzugriff (PDF)

P2Y 2 receptors regulate osteoblast mechanosensitivity during fluid flow

American Journal of Physiology: Cell Physiology, 2014-06, Vol.306 (11), p.C1058-C1067

2014

Volltextzugriff (PDF)

P2Y sub( 2) receptors regulate osteoblast mechanosensitivity during fluid flow

American Journal of Physiology: Cell Physiology, 2014-06, Vol.306 (11), p.C1058-C1058

2014

Volltextzugriff (PDF)

Protein kinase C (PKC) regulates contractility of myometrium from pregnant women

American journal of obstetrics and gynecology, 2006-12, Vol.195 (6), p.S53-S53

2006

Volltextzugriff (PDF)

Role of Protein Kinase Cα in Regulation of [Ca2+]I and Force in Human Myometrium

Reproductive sciences (Thousand Oaks, Calif.), 2009-01, Vol.16 (1), p.71-79

2009

Volltextzugriff (PDF)

T-type calcium(v)3.2 (alpha1H) voltage sensitive calcium channel deficiency negatively impacts skeletal properties and reduces bone formation in a rodent model

Kronbergs, Andris

2011

Volltextzugriff (PDF)

Parathyroid hormone (PTH) mediates shear‐induced actin organization and mechanosensitivity via Ras Homologous A (RhoA) GTPase in osteoblasts

The FASEB journal, 2008-03, Vol.22 (S1)

2008

Volltextzugriff (PDF)

The effect of protein kinase C (PKC) on force and intracellular Ca in uterine smooth muscle from pregnant women

The FASEB journal, 2006-03, Vol.20 (5), p.A1242-A1242

2006

Volltextzugriff (PDF)

Protein Kinase C (PKC)‐mediated actin disruption regulates [Ca2+]i responses to mechanical load in osteoblasts

The FASEB journal, 2007, Vol.21 (6), p.A913-A913

2007

Volltextzugriff (PDF)

Role of Protein Kinase Coc in Regulation of [Ca2+]I and Force in Human Myometrium

Reproductive sciences (Thousand Oaks, Calif.), 2009, Vol.16 (1), p.71-79

2009

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)
Dissertationen
(1)

Sprache

Englisch
(26)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Rheumatology
(9)
Science & Technology
(9)
Humans
(6)
Ixekizumab
(6)
Medicine & Public Health
(4)
Monoclonal Antibodies
(4)
Psoriatic Arthritis
(4)
Antibodies, Monoclonal, Humanized
(3)
Axial Spondyloarthritis
(3)
Medicine
(3)
Non-Radiographic Axial Spondyloarthritis
(3)
Patients
(3)
Physiology
(3)
Psoriasis
(3)
Spondylitis, Ankylosing - Drug Therapy
(3)
Adult
(2)
Ankylosing Spondylitis
(2)
Antirheumatic Agents
(2)
Arthritis
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

P2Y2 receptors regulate osteoblast mechanosensitivity during fluid flow

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

P187 Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year results from the COAST programme

P172 Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF-α inhibitor-experienced) trials at 52 weeks

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial

P2Y^sub 2^ receptors regulate osteoblast mechanosensitivity during fluid flow

P2Y 2 receptors regulate osteoblast mechanosensitivity during fluid flow

P2Y sub( 2) receptors regulate osteoblast mechanosensitivity during fluid flow

Protein kinase C (PKC) regulates contractility of myometrium from pregnant women

Role of Protein Kinase Cα in Regulation of [Ca2+]I and Force in Human Myometrium

T-type calcium(v)3.2 (alpha1H) voltage sensitive calcium channel deficiency negatively impacts skeletal properties and reduces bone formation in a rodent model

Parathyroid hormone (PTH) mediates shear‐induced actin organization and mechanosensitivity via Ras Homologous A (RhoA) GTPase in osteoblasts

The effect of protein kinase C (PKC) on force and intracellular Ca in uterine smooth muscle from pregnant women

Protein Kinase C (PKC)‐mediated actin disruption regulates [Ca2+]i responses to mechanical load in osteoblasts

Role of Protein Kinase Coc in Regulation of [Ca2+]I and Force in Human Myometrium

Suchergebnisse filtern